CDK4 and breast carcinoma: To determine the impact of selective CDK2 inhibition with INX-315 on the transcriptome of CDK4/6i–resistant breast cancer, we treated abemaciclib and abemaciclib/fulvestrant–resistant cells with INX-315 and performed RNA-sequencing.